A number of other equities research analysts also recently commented on the stock. Zacks Investment Research downgraded shares of RedHill Biopharma from a hold rating to a sell rating in a research report on Friday, July 29th. FBR & Co increased their price objective on shares of RedHill Biopharma from $33.00 to $36.00 and gave the company an outperform rating in a research report on Wednesday, July 27th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $26.20.
Shares of RedHill Biopharma (NASDAQ:RDHL) traded up 4.13% on Friday, hitting $14.36. 16,010 shares of the company traded hands. The stock’s 50-day moving average price is $14.70 and its 200-day moving average price is $12.76. RedHill Biopharma has a 12 month low of $8.10 and a 12 month high of $16.54. The company’s market capitalization is $182.86 million.
RedHill Biopharma (NASDAQ:RDHL) last announced its quarterly earnings data on Wednesday, July 27th. The company reported ($0.06) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.58) by $0.52. On average, equities analysts predict that RedHill Biopharma will post ($2.06) earnings per share for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of RDHL. Van ECK Associates Corp boosted its position in shares of RedHill Biopharma by 1.5% in the second quarter. Van ECK Associates Corp now owns 9,623 shares of the company’s stock valued at $105,000 after buying an additional 138 shares during the last quarter. Royal Bank of Canada boosted its stake in shares of RedHill Biopharma by 0.9% in the first quarter. Royal Bank of Canada now owns 21,167 shares of the company’s stock worth $259,000 after buying an additional 191 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new stake in shares of RedHill Biopharma during the second quarter worth $142,000. Finally, Ingalls & Snyder LLC acquired a new stake in shares of RedHill Biopharma during the second quarter worth $451,000. Institutional investors and hedge funds own 15.30% of the company’s stock.
About RedHill Biopharma
Receive News & Ratings for RedHill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.